EMRSA-16

EMRSA-16. It is a major epidemic strain of methicillin-resistant Staphylococcus aureus that emerged in the United Kingdom in the early 1990s and became a dominant cause of healthcare-associated infections. Characterized by its multi-drug resistance and ability to spread efficiently in hospital settings, this strain has been a significant focus of infection control efforts and Public health surveillance. Its impact has been documented in numerous clinical studies and reports from institutions like the Health Protection Agency and the Centers for Disease Control and Prevention.

Characteristics

This strain is classified under SCCmec type II and is typically characterized as ST36 using MLST. It carries the genes for PBP2a, which confers resistance to Methicillin and other beta-lactam antibiotics. Phenotypically, it often exhibits resistance to Erythromycin, Ciprofloxacin, and Gentamicin, but usually remains susceptible to Vancomycin and Linezolid. Research from the Wellcome Trust Sanger Institute has detailed its genomic architecture, including virulence factors like the PVL toxin, although PVL is less commonly associated with this healthcare-associated strain compared to community-associated MRSA clones like USA300.

Epidemiology

First identified in 1992 in the United Kingdom, it rapidly disseminated throughout the NHS hospital network, causing large outbreaks in facilities from London to Glasgow. It subsequently spread to other European countries, including Ireland and the Netherlands, and has been reported in North America and Australia. Surveillance by the ECDC has tracked its prevalence relative to other strains like EMRSA-15. Major reservoirs are colonized patients and healthcare workers, with transmission facilitated by factors such as overuse of fluoroquinolones and lapses in hand hygiene protocols. The COVID-19 pandemic later impacted its circulation due to changes in hospital admission patterns and IPC measures.

Clinical significance

It is a predominant cause of healthcare-associated infections, leading to conditions such as surgical site infections, catheter-related bacteremia, and ventilator-associated pneumonia. Outbreaks have been particularly severe in settings like burn units, neonatal ICUs, and orthopedic wards. Infections are associated with increased mortality, longer hospital stays, and higher treatment costs compared to infections with MSSA. Studies published in journals like The Lancet and Clinical Infectious Diseases have highlighted its role in Sepsis and Endocarditis.

Treatment and resistance

First-line therapy for serious infections typically involves glycopeptides such as Vancomycin or Teicoplanin. Alternatives include oxazolidinones like Linezolid, lipopeptides such as Daptomycin, and the newer cephalosporin Ceftaroline. The strain's resistance to beta-lactams is mediated by the mecA gene. While it generally remains susceptible to first-line agents, reduced susceptibility to Vancomycin (VISA) has been rarely reported, necessitating AST and guidance from institutions like the BSAC. The use of Rifampin or Fusidic acid in combination regimens is sometimes employed for deep-seated infections like Osteomyelitis.

Prevention and control

Controlling its spread requires a multifaceted approach centered on strict contact precautions, including the use of gloves and gowns for patient contact. Core strategies also include rigorous Hand hygiene compliance with alcohol-based rubs, as promoted by campaigns like the WHO's "Clean Care is Safer Care". Active surveillance cultures for high-risk patients upon admission to ICUs are recommended. Successful national decolonization protocols, such as those implemented in the Netherlands (the "Search and destroy" policy), and antimicrobial stewardship programs to reduce unnecessary Ciprofloxacin use have been critical. Ongoing research by the Infection Prevention Society and Public Health England continues to refine outbreak response guidelines.